EGFR/ERBB2 Amplifications and Alterations Associated With Resistance to Lenvatinib in Hepatocellular Carcinoma

Gastroenterology. 2023 May;164(6):1006-1008.e3. doi: 10.1053/j.gastro.2023.01.023. Epub 2023 Jan 26.
No abstract available

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Letter

MeSH terms

  • Antineoplastic Agents* / therapeutic use
  • Carcinoma, Hepatocellular* / drug therapy
  • Carcinoma, Hepatocellular* / genetics
  • Carcinoma, Hepatocellular* / pathology
  • ErbB Receptors / genetics
  • Humans
  • Liver Neoplasms* / drug therapy
  • Liver Neoplasms* / genetics
  • Liver Neoplasms* / pathology
  • Phenylurea Compounds / adverse effects
  • Quinolines* / therapeutic use
  • Receptor, ErbB-2

Substances

  • lenvatinib
  • Phenylurea Compounds
  • Quinolines
  • Antineoplastic Agents
  • ERBB2 protein, human
  • Receptor, ErbB-2
  • EGFR protein, human
  • ErbB Receptors